Form 4: United Therapeutics EVP Paul Mahon Exercises Share Tracking Awards

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised share tracking awards on November 7, 2024, according to a Form 4 filing.

Summary

• Paul Mahon, the EVP & General Counsel of United Therapeutics Corp, executed transactions involving share tracking awards and common stock on November 7, 2024.
• Mahon exercised 7,700 share tracking awards at a price of $163.3, which are non-dilutive cash-settled stock appreciation rights.
• The exercised awards were part of a pre-arranged 10b5-1 plan established on June 20, 2024.
• Following the reported transactions, Mahon directly owns 36,710 shares of common stock and 60,450 share tracking awards.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects routine insider transactions under a pre-arranged plan, indicating confidence in the company's prospects.

Positives

• The exercise of share tracking awards indicates Mahon's continued involvement with the company.
• The use of a pre-arranged 10b5-1 plan suggests transparency and compliance with insider trading regulations.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.
• The exercise of share tracking awards does not dilute the value of common stock as they are cash-settled.

Key Dates